Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial.

By T. Walsh, I. Raad, T. Patterson, P. Chandrasekar, G. Donowitz, R. Graybill, R. Greene, R. Hachem, S. Hadley, R. Herbrecht and 13 more. Clinical Infectious Diseases, 2007

749 citations recorded by the source corpus.

Subfields: Epidemiology, Infectious Diseases, Ophthalmology

View Paper: https://www.semanticscholar.org/paper/57842254e8349aaf598d3a43d69a9c4dce9be9bd

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. M. Arendrup
2. D. Kontoyiannis
3. T. Walsh
4. Thierry Calandra
5. J. Perfect
6. E. Anaissie
7. M. Pfaller
8. D. Diekema

In Infectious Diseases

1. D. Kontoyiannis
2. M. Arendrup
3. G. Dimopoulos
4. J. Roberts
5. J. Fishman
6. J. Perfect
7. E. Anaissie
8. M. Pfaller

Citations in the corpus

• Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper# (2020, background): “Patients with invasive aspergillosis demonstrated improved clinical response with an average posaconazole concentration of > 1 mg/L [151, 152].”
• Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. (2016, background): “Itraconazole and posaconazole have also been successfully used in treatment of CNS aspergillosis [255, 436, 437], and case reports describe the efficacy”
• Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. (2008, background): “A growing body of evidence suggests patient-to-patient variability in the pharmacokinetics of triazoles used for treatment or prophylaxis in invasive aspergillosis [95, 103, 106, 107].”
• Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. (2018, background): “Micafungin 75e200 mg qd C II [572,729] Posaconazole 200 mg qid or 400 mg bid suspension or 300 mg tablet bid day 1, followed by 300 mg qd B II [138,336,730,731]”
• Resistance to Antifungal Agents: Mechanisms and Clinical Impact (2008, background): “As for azole compounds, the increasing use of serum drug levels has begun to emphasize the correlation between direct drug exposure and outcome [111–114].”
• Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. (2008, result): “These data are consistent with the exposure-response relationship recently described for posaconazole, another new-generation triazole [35].”